Peg-ReliGrast 6mg (Pegfilgrastim PFS) 6mg/0.6ml

Peg-ReliGrast 6mg (Pegfilgrastim) is a long-acting form of filgrastim used to support white blood cell recovery. This 6mg/0.6ml pre-filled syringe helps reduce infection risk during chemotherapy. Peg-ReliGrast 6mg injection supports immune function after treatment.

Strength

6mg/0.6ml

Manufacturer / TM Owner

Reliance Life Sciences Pvt Ltd

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Peg-ReliGrast 6mg is used to shorten the duration of neutropenia and reduce infection risk in patients receiving myelosuppressive chemotherapy. It is also used to increase survival in patients acutely exposed to high-dose radiation. Peg-ReliGrast 6mg supports white blood cell production during cancer treatment. It is indicated for patients with non-myeloid malignancies receiving chemotherapy associated with a significant risk of febrile neutropenia.

Side Effects

Peg-ReliGrast 6mg works by stimulating the bone marrow to produce more neutrophils, a type of white blood cell. This helps the body fight infections more effectively during periods of low blood cell counts. Patients may notice improved energy levels as their immune system recovers.

Precautions & Warnings

Store Peg-ReliGrast 6mg in the refrigerator between 2°C and 8°C. Protect from light and avoid freezing. Do not shake the pre-filled syringe. Keep out of reach of children. Dispose of used syringes in a sharps container as directed. Consult a healthcare provider before use if you have sickle cell disorders.

Avoid Interactions

Peg-ReliGrast 6mg may interact with other drugs that affect bone marrow function, such as chemotherapy or radiation therapy. Avoid using lithium unless directed, as it may enhance the effects of Peg-ReliGrast. No known interactions with common medications like pain relievers or antibiotics have been reported.

Frequently Asked Questions

Peg-ReliGrast 6mg is used to reduce infection risk in patients receiving chemotherapy by boosting white blood cell production.

It is given as an injection under the skin, typically 24 hours after chemotherapy.

Common effects may include bone pain or mild fever as the body adjusts to increased white blood cells.

Consult a healthcare provider before use if pregnant or breastfeeding.

Peg-ReliGrast 6mg is available through licensed pharmacies with a prescription.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.